Prevalence of age-related macular degeneration in Spain

Navarro, Joaquín Castro

doi:10.1136/bjo.2010.187773

Cited by 32 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Worldwide, 25 million to 30 million people have severe visual loss due to AMD. The prevalence of AMD in Spain is estimated between 1.3% (65 to 74 years) and 5.7% (aged ≥75 years) of population, accounting for approximately 485.000 potential patients [4]. Since nowadays life expectancy is growing the prevalence of AMD is likely to increase [5], hence its diagnosis and treatment might represent an important challenge.…”

Section: Introductionmentioning

confidence: 99%

Age-Related Macular Degeneration: Clinical Findings following Treatment with Antiangiogenic Drugs

Casaroli-Marano

Gallego-Pinazo

Fernández-Blanco

et al. 2014

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To survey the management of patients with neovascular age-related macular degeneration (nvAMD) in Spain. Methods. An observational retrospective multicenter study was conducted. The variables analyzed were sociodemographic characteristics, foveal and macular thickness, visual acuity (VA), type of treatment, number of injections, and the initial administration of a loading dose of an antiangiogenic drug. Results. 208 patients were followed up during 23.4 months in average. During the first and second years, patients received a mean of 4.5 ± 1.8 and 1.6 ± 2.1 injections of antiangiogenic drugs, and 5.4 ± 2.8 and 3.6 ± 2.2 follow-up visits were performed, respectively. The highest improvement in VA was observed at 3 months of follow-up, followed by a decrease in the response that stabilized above baseline values until the end of the study. Patients who received an initial loading dose presented greater VA gains than those without. Conclusions. Our results suggest the need for a more standardized approach in the management and diagnosis of nvAMD receiving VEGF inhibitors. To achieve the visual outcomes reported in pivotal trials, an early diagnosis, proactive approach (more treating than follow-up visits), and a close monitoring might be the key to successfully manage nvAMD.

show abstract

Section: Introductionmentioning

confidence: 99%

Age-Related Macular Degeneration: Clinical Findings following Treatment with Antiangiogenic Drugs

Casaroli-Marano

Gallego-Pinazo

Fernández-Blanco

et al. 2014

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness in industrialized countries [1,2,3]. The neovascular (or wet) form (nvAMD), involving choroidal neovascularization (CNV) with retinal edema, accounts for the majority of severe vision loss in the disease [4,5].…”

Section: Introductionmentioning

confidence: 99%

Aflibercept as First-Line Therapy in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration: Prospective Case Series Analysis in Real-Life Clinical Practice

et al. 2016

View full text Add to dashboard Cite

Purpose: To assess the 13-month effectiveness and safety of aflibercept in naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting. Methods: Thirty-two treatment-naïve patients with nvAMD participated in a prospective two-center study. Patients received intravitreal injections of aflibercept (Eylea®), a loading dose of three monthly injections (2 mg/0.05 ml) every 4 weeks for the first 3 months, followed by intravitreal injections every 2 months. Results: At 3 and 13 months, the mean best-corrected visual acuity improved significantly as compared with baseline (logMAR 0.53 ± 0.30 and 0.55 ± 0.32 vs. 0.30 ± 0.24, respectively, p < 0.001). At 3 and 13 months, 46.8% of patients (15/32) gained ≥15 ETDRS letters. The mean decrease in central macular thickness was also significant at 3 months (252 ± 35 µm) and at 13 months (249 ± 38 µm) as compared with pretreatment values (383 ± 76 µm) (p < 0.01). Also, 50% resolution of pigment epithelial detachment (PED) was observed in 8 out of 9 eyes (88.9%) with PED at baseline. Intravitreal injections were well tolerated and no adverse events were recorded. Conclusion: Aflibercept was effective and safe for treating nvAMD in naïve patients in routine daily practice.

show abstract

“…Even when AMD does not lead to blindness, there is a strong negative impact on the independence and the quality of life. [20] Despite the magnitude of this problem, very few factors have been identified as capable to modify the natural course of AMD once signs of early -small-intermediate hard drusen (≤ 124 µm) and/or retinal pigment epithelium (RPE) changes- or intermediate –some large soft drusen (>124 µm) and/or geographic atrophic patches without central macular involvement- AMD appear.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal Docosahexaenoic Acid in a Rabbit Model: Preclinical Safety Assessment

et al. 2014

View full text Add to dashboard Cite

PurposeThe purpose of the present study was to evaluate the retinal toxicity of a single dose of intravitreal docosahexaenoic acid (DHA) in rabbit eyes over a short-term period.MethodsSixteen New Zealand albino rabbits were selected for this pre-clinical study. Six concentrations of DHA (Brudy Laboratories, Barcelona, Spain) were prepared: 10 mg/50 µl, 5 mg/50 µl, 2’5 mg/50 µl, 50 µg/50 µl, 25 µg/50 µl, and 5 µg/50 µl. Each concentration was injected intravitreally in the right eye of two rabbits. As a control, the vehicle solution was injected in one eye of four animals. Retinal safety was studied by slit-lamp examination, and electroretinography. All the rabbits were euthanized one week after the intravitreal injection of DHA and the eyeballs were processed to morphologic and morphometric histological examination by light microscopy. At the same time aqueous and vitreous humor samples were taken to quantify the concentration of omega-3 acids by gas chromatography. Statistical analysis was performed by SPSS 21.0.ResultsSlit-lamp examination revealed an important inflammatory reaction on the anterior chamber of the rabbits injected with the higher concentrations of DHA (10 mg/50 µl, 5 mg/50 µl, 2'5 mg/50 µ) Lower concentrations showed no inflammation. Electroretinography and histological studies showed no significant difference between control and DHA-injected groups except for the group injected with 50 µg/50 µl.ConclusionsOur results indicate that administration of intravitreal DHA is safe in the albino rabbit model up to the maximum tolerated dose of 25 µg/50 µl. Further studies should be performed in order to evaluate the effect of intravitreal injection of DHA as a treatment, alone or in combination, of different retinal diseases.

show abstract

Prevalence of age-related macular degeneration in Spain

Abstract: The prevalence of AMD in this large, population-based Spanish sample was similar to that observed in other large-scale population-based studies. However, the prevalence of ARM was lower than found in similar studies.

Cited by 32 publications

References 28 publications

Age-Related Macular Degeneration: Clinical Findings following Treatment with Antiangiogenic Drugs

Age-Related Macular Degeneration: Clinical Findings following Treatment with Antiangiogenic Drugs

Aflibercept as First-Line Therapy in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration: Prospective Case Series Analysis in Real-Life Clinical Practice

Intravitreal Docosahexaenoic Acid in a Rabbit Model: Preclinical Safety Assessment

Contact Info

Product

Resources

About